News headlines about G1 Therapeutics (NASDAQ:GTHX) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. G1 Therapeutics earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.7968207496755 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several analysts have issued reports on GTHX shares. BidaskClub cut G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. BTIG Research started coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price on the stock. Zacks Investment Research cut G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. increased their target price on G1 Therapeutics to $30.00 in a research report on Monday, February 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. G1 Therapeutics has an average rating of “Buy” and an average target price of $32.80.
G1 Therapeutics (NASDAQ:GTHX) traded up $0.03 during trading on Friday, hitting $20.10. The stock had a trading volume of 64,700 shares, compared to its average volume of 73,836. G1 Therapeutics has a 52-week low of $12.04 and a 52-week high of $28.67.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.